12月3日 - ** 精准肿瘤公司Black Diamond Therapeutics BDTX.O股价盘前上涨3.8%至3.58美元
** 该公司称其实验性抗癌药物西来替尼（silevertinib）达到了主要目标，在43名罕见表皮生长因子受体（EGFR）突变的肺癌患者中取得了60%的肿瘤反应和86%的脑部反应
** 表皮生长因子受体（EGFR）是一种帮助细胞生长的蛋白质，突变可诱发癌症
** 另外，公司表示计划在 2026 年上半年开始对胶质母细胞瘤（一种侵袭性脑癌）患者进行西利韦替尼的中期试验。
** 截至上日收盘，股价累计上涨 61
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.